TRAIL Based Therapy: Overview of Mesenchymal Stem Cell Based Delivery and miRNA Controlled Expression of TRAIL

  • Attar, Rukset (Department of Obstetrics and Gynecology, Yeditepe University Hospital) ;
  • Sajjad, Farhana (Department of Anatomy, Allama Iqbal Medical College) ;
  • Qureshi, Muhammad Zahid (Department of Chemistry, GCU) ;
  • Tahir, Fizza (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College) ;
  • Hussain, Ejaz (Department of Botany, GCU) ;
  • Fayyaz, Sundas (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College) ;
  • Farooqi, Ammad Ahmad (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College)
  • Published : 2014.08.30


Rapidly increasing number of outstanding developments in the field of TRAIL mediated signaling have revolutionized our current information about inducing and maximizing TRAIL mediated apoptosis in resistant cancer cells. Data obtained with high-throughput technologies have provided finer resolution of tumor biology and now it is known that a complex structure containing malignant cells strictly coupled with a large variety of surrounding cells constitutes the tumor stroma. Utility of mesenchymal stem cells (MSCs) as cellular vehicles has added new layers of information. There is sufficient experimental evidence substantiating efficient gene deliveries into MSCs by retroviral, lentiviral and adenoviral vectors. Moreover, there is a paradigm shift in molecular oncology and recent high impact research has shown controlled expression of TRAIL in cancer cells on insertion of complementary sequences for frequently downregulated miRNAs. In this review we have attempted to provide an overview of utility of TRAIL engineered MSCs for effective killing of tumor and potential of using miRNA response elements as rheostat like switch to control expression of TRAIL in cancer cells.


TRAIL;Apoptosis;targeted therapy;signaling cascades


  1. Akimoto K, Kimura K, Nagano M, et al (2013). Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev, 22, 1370-86.
  2. Deng Q, Zhang Z, Feng X, et al (2014). TRAIL-secreting mesenchymal stem cells promote apoptosis in heat-shocktreated liver cancer cells and inhibit tumor growth in nude mice. Gene Ther, 21, 317-27.
  3. Huo W, Jin N, Fan L, Wang W (2014). MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells. Mol Cell Biochem, 388, 123-33.
  4. Kim SM, Woo JS, Jeong CH, et al (2014). Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med, 3, 172-82.
  5. Kim SW, Kim SJ, Park SH, et al (2013). Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res, 19, 415-27.
  6. Nesterenko I, Wanningen S, Bagci-Onder T, et al (2012). Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One, 7, e49219
  7. Sage EK, Kolluri KK, McNulty K, et al (2014). Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax, 69, 638-47.
  8. Yan C, Li S, Li Z, et al (2013). Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non- Hodgkin's lymphoma. Mol Pharm, 10, 142-51.
  9. Yan C, Yang M, Li Z, et al (2014). Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cordderived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. Biomaterials, 35, 3035-43.
  10. Yu R, Deedigan L, Albarenque SM, et al (2013). Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death Dis, 4, e503.
  11. Yulyana Y, Endaya BB, Ng WH, et al (2013).Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. Stem Cells Dev, 22, 1870-82.
  12. Zhou K, Yan Y, Zhao S (2014). Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122. Tumour Biol, 35, 5787-95.
  13. Kim SM, Woo JS, Jeong CH, et al (2012). Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res, 72, 4807-17.
  14. Ding H, Wu YL, Wang YX, Zhu FF (2014). Characterization of the microRNA expression profile of cervical squamous cell carcinoma metastases. Asian Pac J Cancer Prev, 15, 1675-9.
  15. Farooqi AA, Qureshi MZ, Coskunpinar E, et al (2014). miR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis. Asian Pac J Cancer Prev, 15, 1909-12.
  16. Zhou RP, Chen G, Shen ZL, Pan LQ (2014). Cinobufacin suppresses cell proliferation via miR-494 in BGC-823 gastric cancer cells. Asian Pac J Cancer Prev, 15, 1241-5.
  17. Diao CY, Guo HB, Ouyang YR, et al (2014). Screening for metastatic osteosarcoma biomarkers with a DNA microarray. Asian Pac J Cancer Prev, 15, 1817-22.
  18. Orang AV, Safaralizadeh R, Hosseinpour Feizi MA (2014). Insights into the Diverse Roles of miR-205 in Human Cancers. Asian Pac J Cancer Prev, 15, 577-83.
  19. Mollaie HR, Monavari SH, Arabzadeh SA, et al (2013). RNAi and miRNA in viral infections and cancers. Asian Pac J Cancer Prev, 14, 7045-56.

Cited by

  1. TRAIL Suppresses Human Breast Cancer Cell Migration via MADD/CXCR7 vol.16, pp.7, 2015,
  2. Opposite Effects of Coinjection and Distant Injection of Mesenchymal Stem Cells on Breast Tumor Cell Growth vol.5, pp.9, 2016,
  3. Co-culture with lung cancer A549 cells promotes the proliferation and migration of mesenchymal stem cells derived from bone marrow vol.14, pp.4, 2017,
  4. The Use of Normal Stem Cells and Cancer Stem Cells for Potential Anti-Cancer Therapeutic Strategy vol.15, pp.4, 2018,